EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

4-Methylcatechol attenuates diabetic myocardial disorder via the ESR1–PI3K–AKT pathway

Zong-Hao Zhang, Ji-Fan Qian, Zehua Zhou, Jun-Xi Yin, Shi-Tao Zhou, Zhi-Hui Fang, Wei Qi, Hai-Yun Mao, Xiao-Jiang Wang, Rui Chen, Cheng-Zhi Fang, Hang Zhang und 2 weitere

Frontiers in Pharmacology · 09.04.2026 · 17

DOI: 10.3389/fphar.2026.1801465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.04.2026. Verfasst von Zong-Hao Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research Center, Pu'er People's Hospital, Pu'er, Yunnan, China. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Diabetic myocardial disorder is a severe complication of diabetes mellitus, in which hyperglycemia and hyperlipidemia play pivotal roles in its pathogenesis.

Objective

This study aimed to investigate the protective effects of 4-methylcatechol (4-MC) against diabetic myocardial injury and to elucidate its underlying mechanisms, using a high glucose and palmitic acid (HG/PA)-induced AC16 cardiomyocyte injury model. Materials and methods: To investigate 4-Methylcatechol (4-MC), potential therapeutic targets were first identified via bioinformatics, followed by molecular docking to analyze binding to the core target and KEGG/GO enrichment analyses to identify critical pathways, with final in vitro validation in AC16 cells assessing effects on HG/PA-induced oxidative stress and apoptosis, using pharmacological inhibitors to confirm the specific signaling axis.

Results

Bioinformatics analysis identified ESR1 as a potential core therapeutic target of 4-MC. Molecular docking revealed that 4-MC forms stable hydrogen bonds with Arg394 and Lys449 residues within the ESR1 binding pocket. KEGG/GO enrichment analyses further indicated that the modulation of oxidative stress, apoptosis, and energy metabolism constitutes the critical pathways mediating 4-MC’s therapeutic effects. In vitro experiments demonstrated that 4-MC significantly mitigates HG/PA-induced oxidative stress and intrinsic apoptosis in cardiomyocytes. Notably, this cardioprotection was abolished upon treatment with the ESR1 antagonist Fulvestrant or the PI3K inhibitor LY294002, validating that 4-MC exerts its protective effect specifically through the ESR1-PI3K-AKT signaling axis.

Conclusion

4-Methylcatechol alleviates diabetic myocardial disorder by activating the ESR1-PI3K-AKT pathway, offering novel therapeutic targets and a candidate compound for intervention.

Schlagwörter

Stichwörter der Autor:innen

4-methylcatecholESR1PI3K-Akt pathwayapoptosisdiabetic myocardial disordermitochondriaoxidative stress

Autor:innen und Institutionen

  • Research Center, Pu'er People's Hospital, Pu'er, Yunnan, China.
  • Research Center, Pu'er People's Hospital, Kunming University of Science and Technology Affiliated Hospital, Pu'er, Yunnan, China.
  • Research Center, Pu'er People's Hospital, School of Medicine, Kunming University of Science and Technology, Pu'er, Yunnan, China.
  • The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, Sichuan, China.
  • Department of Radiology, Pu'er People's Hospital, Pu'er, Yunnan, China.
  • Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Z. H., Qian, J. F., Zhou, Z., Yin, J. X., Zhou, S. T., Fang, Z. H., Qi, W., Mao, H. Y., Wang, X. J., Chen, R., Fang, C. Z., Zhang, H., Yang, H. H., & Hou, K. (2026). 4-Methylcatechol attenuates diabetic myocardial disorder via the ESR1–PI3K–AKT pathway. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1801465

Vancouver

Zhang ZH, Qian JF, Zhou Z, Yin JX, Zhou ST, Fang ZH, et al. 4-Methylcatechol attenuates diabetic myocardial disorder via the ESR1–PI3K–AKT pathway. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1801465

BibTeX
@article{Zhang2026,
  author = {Zhang, Zong-Hao and Qian, Ji-Fan and Zhou, Zehua and Yin, Jun-Xi and Zhou, Shi-Tao and Fang, Zhi-Hui and Qi, Wei and Mao, Hai-Yun and Wang, Xiao-Jiang and Chen, Rui and Fang, Cheng-Zhi and Zhang, Hang and Yang, Hai-Hui and Hou, Kai},
  title = {4-Methylcatechol attenuates diabetic myocardial disorder via the ESR1–PI3K–AKT pathway},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1801465}
}
Kostenlos starten →